GH Research PLC

NASDAQ•GHRS

CEO: Mr. Florian Schonharting M.Sc. (Econ)

セクター: Healthcare

業種: Biotechnology

上場日: 2021-06-25

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

連絡先情報

Joshua Dawson House, Dawson Street, Dublin, D02 RY95, Ireland

353-1-437-8334

www.ghres.com

時価総額

$991.85M

PER (TTM)

-23.1

19.7

配当利回り

52週高値

$19.51

52週安値

$7.98

52週レンジ

69%

順位58Top 85.6%

2.3

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 2.3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.23+0.00%

直近4四半期の推移

フリーCF

-$14.48M+17.64%

直近4四半期の推移

2024 FY 決算ハイライト

主なハイライト

GH001 TRD Trial Success Primary endpoint met in TRD Phase 2b trial; GH001 achieved -15.2 point MADRS reduction versus placebo on Day 8.

Research Spending Rises Research and development expenses increased $5.2 M to $35.0 M in 2024, driven by advancing clinical trial activities.

Cash Reserves Remain Strong Cash and equivalents totaled $100.8 M as of December 31, 2024, supporting operations for at least the next 12 months.

GH002 Phase 1 Complete Completed Phase 1 pharmacology trial for intravenous candidate GH002 in healthy volunteers; top-line results available.

リスク要因

Expect Continued Operating Losses Incurred net loss of $39.0 M in 2024; expects significant operating losses to continue for the foreseeable future.

FDA Hold Response Pending FDA clinical hold on GH001 IND requires toxicology studies; planned response submission scheduled for mid-2025.

Need Substantial Additional Funding Requires substantial additional funding to pursue growth strategy; failure to raise capital delays development programs or commercialization.

Mebufotenin Scheduling Risk Mebufotenin is Schedule I in US; rescheduling required for marketing, dependent on FDA approval and DEA action.

見通し

Resolve GH001 FDA Hold Preparing complete response to FDA clinical hold regarding GH001 device bridging data; planned submission mid-2025.

Complete GH001 Extension Phase Open-label extension phase for TRD trial on track for last patient visit completion in first quarter of 2025.

Advance GH002 Program Anticipate developing intravenous candidate GH002 further following completion of Phase 1 pharmacology trial results.

Establish Commercial Capabilities Plans to establish sales, marketing, distribution, and commercial infrastructure to support potential future product approvals.

同業比較

売上高 (TTM)

AKBA

$236.19M

+47.5%

VALN

$198.55M

+13.5%

GERN

$183.88M

+138.8%

粗利益率 (最新四半期)

NBTX

100.0%

+0.0pp

ABUS

97.9%

-2.1pp

GERN

97.3%

-45.2pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
TYRA	$1.88B	-17.5	-41.2%	2.1%
NBTX	$1.74B	-26.5	76.7%	113.4%
PVLA	$1.60B	-45.5	-64.4%	23.9%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月5日

EPS:-$0.29

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし